ZURA
Zura Bio Ltd - Ordinary Shares - Class A

1,103
Mkt Cap
$550.94M
Volume
406,180.00
52W High
$7.19
52W Low
$0.97
PE Ratio
-9.35
ZURA Fundamentals
Price
$6.62
Prev Close
$6.77
Open
$6.75
50D MA
$5.62
Beta
1.22
Avg. Volume
943,067.95
EPS (Annual)
-$0.6046
P/B
3.98
Rev/Employee
$0.00
$24.38
Loading...
Loading...
News
all
press releases
Zura Bio Announces Closing of its $144 Million Public Offering and Full Exercise of the Underwriters Option to Purchase Additional Shares
Zura Bio Limited (Nasdaq: ZURA) (Zura), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and...
Business Wire·2d ago
News Placeholder
More News
News Placeholder
Zura Bio Announces Pricing of $125 Million Public Offering of Class A Ordinary Shares and Pre-Funded Warrants
Zura Bio Limited (Nasdaq: ZURA), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating...
Business Wire·4d ago
News Placeholder
Zura Bio Announces Proposed Public Offering of Class A Ordinary Shares and Pre-Funded Warrants
Zura Bio Limited (Nasdaq: ZURA), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating...
Business Wire·5d ago
News Placeholder
Zura Bio Welcomes Accomplished Drug Development Leaders Mark Eisner, M.D., M.P.H., and Ajay Nirula, M.D., Ph.D., to Board of Directors
Zura Bio Limited (Nasdaq: ZURA) (Zura or the Company), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious...
Business Wire·6d ago
News Placeholder
Zura Bio Limited (NASDAQ:ZURA) Receives Average Rating of "Moderate Buy" from Brokerages
Shares of Zura Bio Limited (NASDAQ:ZURA - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the seven ratings firms that are covering the firm, MarketBeat.com reports...
MarketBeat·7d ago
News Placeholder
Zura Bio Highlights Key Phase 2 Tibulizumab Readouts at Guggenheim Biotech Summit 2026
Zura Bio (NASDAQ:ZURA) outlined its near-term clinical milestones and strategy at Guggenheim Securities' Emerging Outlook Biotech Summit 2026, emphasizing upcoming Phase 2 readouts for its lead...
MarketBeat·13d ago
News Placeholder
Zura Bio Limited (NASDAQ:ZURA) Short Interest Up 27.7% in January
Zura Bio Limited (NASDAQ:ZURA - Get Free Report) was the recipient of a large growth in short interest in January. As of January 30th, there was short interest totaling 3,847,872 shares, a growth of...
MarketBeat·14d ago
News Placeholder
Zura Bio (NASDAQ:ZURA) Coverage Initiated at Wedbush
Wedbush started coverage on shares of Zura Bio in a research note on Monday. They issued an "outperform" rating and a $15.00 target price for the company...
MarketBeat·20d ago
News Placeholder
Zura Bio Limited (NASDAQ:ZURA) Given Average Rating of "Moderate Buy" by Brokerages
Shares of Zura Bio Limited (NASDAQ:ZURA - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the six analysts that are covering the firm, Marketbeat Ratings reports. One...
MarketBeat·1mo ago
News Placeholder
Zura Bio (NASDAQ:ZURA) Trading Up 0.3% - What's Next?
Zura Bio (NASDAQ:ZURA) Trading 0.3% Higher - Still a Buy...
MarketBeat·1mo ago
<
1
2
...
>

Latest ZURA News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.